Walleye Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Walleye Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02M	Buy	+12,780	New	+$1.73M	0.01%	1505
2025 Q1	–	Sell	-134,006	Closed	-$12M	–	5236
2024 Q4	$12.1M	Sell	134,006 -26,619	-17%	-$2.58M	0.03%	526
2024 Q3	$15.9M	Sell	160,625 -7,701	-5%	-$757K	0.03%	443
2024 Q2	$15.6M	Buy	168,326 +102,801	+157%	+$9.22M	0.03%	492
2024 Q1	$6.22M	Buy	+65,525	New	+$6.08M	0.01%	1147
2021 Q1	–	Sell	-4,826	Closed	-$679K	–	1372
2020 Q4	$679K	Buy	+4,826	New	+$618K	0.05%	379

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Walleye Capital's XBI Position: Q2 2026 in Review

Walleye Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 12,780 shares worth $2.02M. The stake represents 0.01% of the portfolio and ranks #1505 among its holdings. This is a return to the name: Walleye Capital previously reported a position in XBI as recently as Q4 2024.

Walleye Capital first reported a position in XBI in Q4 2020 and has held it in 6 quarters since. The position peaked at $15.9M in Q3 2024. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Walleye Capital held 12,780 shares of State Street SPDR S&P Biotech ETF worth $2.02M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Walleye Capital position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1505 holding.
Walleye Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 6 quarters since.
Walleye Capital's State Street SPDR S&P Biotech ETF position peaked at $15.9M in Q3 2024.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.